Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

Fig. 4

Immune activation and beneficial modulation of the TME by EnanDIM® molecules in vivo. S.c. injection of 10 mg EnanDIM-C, 50 mg EnanDIM-A or vehicle (0.9% NaCl) into female CD-1 mice and determination of IP-10 concentration (a) and frequency of CD169+ monocyte (CD11b + CD11c-) (b) after 24 h from blood samples. c, IP-10 serum levels measured at different time points after s.c. injection of indicated amounts of EnanDIM-C (left) or EnanDIM-A (right) into female Balb/c mice. d-i, impact of EnanDIM-C on the TME in vivo. d, Balb/c mice were inoculated s.c. with CT26 tumor cells. Established tumors (app. 140mm3, day 10) were injected with EnanDIM-C (i.tu.) or vehicle as control. Mice were sacrificed at day 21 for tumor preparation. e, mean tumor growth (+ SEM). f, tumor growth from individual mice (top: vehicle, bottom: EnanDIM-C) – inlay: example of tumor at sacrifice. g, examples of CD8+ staining (frozen sections). h, scoring of CD8+ cells in tumor periphery (**p ≤ 0.01, left) or tumor center (*p ≤ 0.05, right) from 7 mice per group, Mann-Whitney test was used. i, CD8+ T cell score vs tumor volume at day 21 in tumor periphery (left) or tumor center (right), correlation coefficients r and p-values from Pearson correlation analyses

Back to article page